Triplet-targeted therapy improves survival for patients with advanced colorectal cancer and BRAF mutations
Abstract: LBA32
The three-drug combination of encorafenib, binimetinib and cetuximab significantly improved overall survival (OS) in patients with BRAF-mutated metastatic colorectal cancer (mCRC), according to results of the BEACON CRC Phase III clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.
The treatment combination resulted in median OS of 9 months for the combination therapy compared...
MD Anderson honored to rank as nation’s best hospital for cancer care in annual survey
The University of Texas MD Anderson Cancer Center is honored to be ranked No. 1 in cancer care in the U.S. News & World Report’s annual...